Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Nov 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 Planned End Date changed from 9 Nov 2021 to 10 Dec 2021.
- 31 Oct 2018 Planned initiation date changed from 27 Sep 2018 to 5 Nov 2018.